Replimune Group, Inc.’s Registered Equity Offering

Cravath represented the underwriters, led by J.P. Morgan Securities, SVB Leerink and Barclays, in connection with the $287.5 million registered equity offering of Replimune Group, Inc., a biotechnology company developing oncolytic immuno‑gene therapies derived from its Immulytic™ platform. The offering consisted of shares of Replimune’s common stock and pre‑funded warrants to acquire shares of its common stock. The shares were listed on The Nasdaq Global Select Market.

The Cravath team included partner William V. Fogg and associates Eric S. Goodwin, Parth S. Baxi and Kevin L. Cheng on capital markets matters, partner Christopher K. Fargo and associates Richard Bohm and Carlos Nicholas Obando on tax matters, and partner David J. Kappos and associate Carys Webb on intellectual property matters.